 ii
  
中文摘要 
目前我們已完成 9 個與行為異常相關基因 (Gβ3、InFG、ADA、
DRD2A、DRD2β、HTR2A、COMT、ADRA1R、DRD3) 的基因型分
析方法，且已完成控制組的分析實驗。檢體收集已完成部分仍待更進
一步收集，以完成足夠及具有統計意義的檢體數目，盼望第三期的計
畫實施，可以順理完成全部程序。 
 iv 
表   目   錄 
 
表 1 5 % Chelex 100  17 
表 2 10 mg/mL Proteinase K 17 
表 3 To extract DNA(hair)  18 
表 4 To extract DNA(Oral Swbs)  18 
表 5 Primers used for PCR amplification of CYP2A6  25 
表 6 PCR primers for the G-148A and G-353A polymorphism of the PNMT gene 33 
表 7 Prevalence of T/T, T/C, and C/C genotypes 35 
表 8 Frequency of the T and C allele 35 
表 9 Prevalence of A/A, A/G, and G/G genotypes 36 
表 10 Frequency of the A and G allele 36 
表 11 Prevalence of M/M, M/N, and N/N genotypes 37 
表 12 Frequency of the M and N allele 37 
表 13 Prevalence of A1/A1, A1/A2, and A2/A2 genotypes 38 
表 14 Frequency of the A1 and A2 allele 38 
表 15 Prevalence of B1/B1, B1/B2, and B2/B2 genotypes 39 
表 16 Frequency of the B1 and B2 allele 39 
表 17 Prevalence of T/T, T/C, and C/C genotypes 40 
表 18 Frequency of the H and L allele 40 
表 19 Prevalence of H/H, H/L, and L/L genotypes 41 
表 20 Frequency of the H and L allele 41 
 vi 
圖   目   錄 
 
圖 1 The Polymerase chain reaction (PCR) amplification of 
region downstream from the polyadenylation signal 34 
圖 2 The Polymerase chain reaction (PCR) amplification of 
region downstream from the G5644 polymorphism 
signal 
36 
圖 3 The ADA locus encompasses 12 exons spanning 
approximately 32 Kb and is located on chromesome 20q 
13.11 
37 
圖 4 The Polymerase chain reaction (PCR) amplification of 
region downstream from the polyadenylation signal 38 
圖 5 The Polymerase chain reaction (PCR) amplification of 
region downstream from the polyadenylation signal 39 
圖 6 Primer flanking the 5-HTR2A polymorphic site at 
position 102 were use to generate a 342bp fragment 40 
圖 7 The Polymerase chain reaction (PCR) amplification of 
exon 4 of the COMT gene 41 
圖 8 The Polymerase chain reaction (PCR) amplification of 
α1a-adrenoceptor genotype 42 
圖 9 The Polymerase chain reaction (PCR) amplification of 
region downstream from the polyadenylation signal 43 
圖 10 The Polymerase chain reaction (PCR) amplification of 
region downstream from the C825T polymorphism 
signal 
54 
圖 11 The ADA locus encompasses 12 exons spanning 
approximately 32 Kb and is located on  chromesome 
20q 13.11 
55 
 1
前言 
工安事故之發生除造成勞工本身及周遭人員之傷害、殘廢或死亡
外，亦導致事業單位財產、設備及營運之重大損失與災害處理上之精
神負擔，甚至影響及於箱關人員之家庭，衍生重大的社會問題，對國
家造成難以估計的社會損失；根據行政院勞委會勞工安全衛生研究所
之研究報告指出，我國全產業勞工因工死亡千人率，較英國高八倍，
較日本高四倍，較美國高出一倍（勞工安全衛生研究所，1996），顯
示出我國在職業安全方面的工作，與先進國家比較仍然落後很多，依
然有非常大的空間需要努力。 
前述報告中亦可發現，即使是低死亡千人率的工業先進國家，
如：英國、德國、日本等，常因發生巨大工安事故，導致某年之死亡
千人率急劇上升，此現象充分顯示，即使在工業先進國家，仍然無法
根絕巨大工業災害之發生。也因此，工安事故的發生一直是全世界產
業界揮之不去的威脅，降低事故的發生更是安全衛生工作上，大家共
同的終極目標。 
工安事故之發生，或是一時衝動，或是平日工作養成不良習性，
或是具叛逆性違反正常工作程序或守則，以致釀成大錯，鑄成安全上
的威脅，九成左右的所有工安事故均與行為有關。Attention Deficit 
Hyperactive Disease（ADHD）、毒品藥物成癮、pathological gambling、
過食症（overeating）等，都是屬於衝動性、成癮性及強迫性異常行
為（impulsive-addictive-compulsive disorder，IACD），這類 IACD 行
為，Blum 等將其歸納為「回饋缺乏症」"Reward Deficiency Syndrome"
（Blum, Holder, Cull, 陳振和，1998），而此症與特定基因有明顯的關
聯性。本計畫將探討造成重大工安事故者的肇事行為與 IACD 的相關
性，並就與 IACD 有明顯關聯性的特定基因，進行重大工安事故肇事
者與這些特定基因之間，彼此關聯性的探討。 
 3
文獻探討 
1.安全與行為 
早於 1913 年 Watson 就提出「行為」的觀念，他認為應該把重
點放在「可觀察」的行為上（Watson, 1913），此觀念為以行為為基
準的安全觀念（behavior-based safety, BBS）提供最早的基礎。
Heinderich 於 1931 年提出百分之八十八的所有工安事故，是由於不
安全的行為所造成，並建議安全管理應著重於行為上，以降低工安
事故的發生（Petersen, 2000）。Pollina 則在 1962 年以品質管制的觀
念，提出安全行為取樣的方法（Pollina, 1962），曾被成功地應用在
重型製造業，但目前已甚少被使用。在過去的十年來，以行為為基
準的安全觀念，被非常廣泛地討論，並已廣泛的被接受（Krause, 
1990；Loafmann, 1998；Geller, 2000）。 
根據美國職業安全衛生署（OSHA）的國家職業安全衛生研究
所（National Institute for Occupational Safety and Health）之國家安全
資料庫（NASD）的資料顯示，美國有百分之八十五至九十八的所
有工安事故，皆是由於員工不安全的行為所造成（NIOSH, 1999），
此資料為工安事故與行為間的關係，提供最佳的佐證。 
2.回饋缺乏症（Reward Deficiency Syndrome） 
衝動性、成癮性及強迫性異常行為（ impulsive- addictive- 
compulsive disorder）IACD，造成無數的衝動及成癮行為，包括：
酒精中毒（Blum, et al, 1990）、多種毒藥物的濫用（Blum, et al., 
1989）、抽煙（Noble, 1994）、過食症（Blum, Braverman, TJH Chen et. 
al., 1996）、過動兒 （attention deficit hyperactivity disorder，ADHD)
（Blum, Lubar, TJH Chen et. al）以及病理性賭癮（pathological 
gambling）（Comings, et al., 1996）， IACD 甚至被認為是對人類健
康的頭號威脅；在過去十年間，科學家努力鑽研基因與 IACD 的關
聯性，由分子基因學的觀點來看，關聯性係指某一基因變異體 (a 
 5
c.工安事故與基因關聯性 
工安事故與行為科學中最根本的基因問題之間的研究，截至
目前，文獻中還找不到任何相關的研究成果發表，因此，本計畫
建立「工安事故與基因關聯性研究室」之後，所欲從事的研究「工
安事故與特定基因之關聯性探討」，係屬創新的研究，即使是世
界先進各國仍無類似的研究結果。 
 7
結果與討論 
1. General population Control 
本研究得到的General population Control的結果與文獻中記載的
結果幾乎完全一致，在誤差範圍之內。 
2. Super Control 
採用之 Super Control，由於最後結果因問卷重新更正，加上由
City of Hope 醫學院，曾任 American Medical Genetics Association 的
President 的 Dr. David Comings 建議加入其問卷內容，尚在重新整理
當中，新的問卷長達三十餘頁，會是一件相當繁複的工作。 
3. 罹職災者檢體 
罹職災者檢體是透過高雄市勞工局與社會局之資料，由高雄是
兩萬六千多名的身心障礙者當中，篩選出 387 位曾經罹職災者一個一
個打電話訪談，經過數週的努力，僅僅收集到七位檢體，仍將持續努
力收集更多檢體，但初步分析罹職災者檢體的結果相當令人振奮。 
4.檢體基因分析結果 
a. Gene Gβ3： 無明顯差異，敬請參見表 7、表 8、表 21 及表 22；
general control, T/T=30.0%, T/C=55.4%, C/C=14.6%, T=57.7%, 
C=42.3% ； Samples, T/T=25.0%, T/C=62.5%, C/C=0.0%, 
T=56.3%, C=31.3%. 
b. Gene ADA： 無明顯差異，敬請參見表 11、表 12、表 27 及表
28 ； general control, M/M=0.0%, M/N=9.2%, N/N=90.8%, 
M=57.7%, N=42.3% ；  Samples, M/M=0.0%, M/N=0.0%, 
N/N=100.0%, M=0.0%, N=100.0%. 
c. Gene DRD2A： DRD2A Gene 有非常令人訝異的結果，敬請參
見表 13、表 14、表 29 及表 30；general control, A1/A1=14.6%, 
A1/A2=64.6%, A2/A2=20.8%, A1=46.9%, A2=53.1%； Samples, 
A1/A1=0.0%, A1/A2 =100.0%, A2/A2=0.0%, A1=50.0%, 
 9
研究成果 
一、 SCI 期刊論文 
1. Thomas JH Chen, Eric R. Braverman, et al. (2008) “Hypothesizing that 
Marijuana smokers are at a significantly lower risk of carcinogenicity relative 
to tobacco-non-Marijuana smokers: evidenced based on statistical 
re-evaluation of current literature.” Jurnal of Psychoactive Drugs. (in press) 
(SSCI) 
2. Thomas JH Chen, Kenneth Blum, et al. (2007) Chromium Picolinate (CrP) a 
putative anti-obesity nutrient induces changes in body composition as a 
function of the Taq1 dopamine D2 receptor polymorphisms in a randomized 
double –blind placebo controlled study. Gene Therapy & Mol Biology,11(B): 
161-170.  (SCI). 
3. Eric R Braverman, Thomas JH Chen, et al. Plasma Growth Hormones, P300 
Event-Related Potential and Test Of Variables of Attention (T.O.V.A.) (2007) 
Are Important Neuroendocrinological Predictors of Early Cognitive Decline 
in a Clinical Setting: Evidence supported by PATH Analysis. Age, 11(11): 
1013-1031. (SCI) 
4. Blum, Kenneth, Thomas J.H. Chen, et al. (2007) Manipulation of 
Catechol –O Methyl Transferase (COMT)Activity to influence the attenuation 
of substance seeking behavior, a subtype of Reward Deficiency Syndrome 
(RDS), is dependent upon gene polymorphisms. A Hypothesis. Medical 
Hypotheses, 69: 1054-1060. (SCI) 
5. Chen, TJH, K Blum, et al. (2007) “Preliminary Association of both the Taq1 
A1 Allele of the Dopamine D2 Receptor Gene and the Dopamine Transporter 
(DAT1) 480 bp Allele with Pathological Aggressive Behavior in Adolescents: 
A Putative Subtype of Reward Deficiency Syndrome (RDS).” Gene Therapy 
& Mol Biology, 11A: 93-112. (SCI) 
6. Thomas JH Chen, Kenneth Blum, et al. (2007) Reviewing the role of putative 
candidate genes in “Neurobesigenics” a clinical subtype of Reward 
Deficiency Syndrome(RDS). Gene Therapy & Mol Biology, 11A:61-74. (SCI) 
7. Thomas JH Chen, Kenneth Blum, et al. (March/April, 2007) "Gene Narcotic 
Attnuation Program Attenuates Substance Use Disorder, a Clinical Subtype of 
Reward Deficiency Syndrome." Advances in Therapy, 24(2): 402-14. (SCI） 
8. Kenneth Blum, Thomas JH Chen, et al. (2007) The PPAR-gamma Pro12Ala 
 11
Complex Behavioral Disorders. Medical Hypotheses. 65(4): 703-7.（SCI） 
19. Blum, K, TJH Chen & BD Ross. (May, 2005) Innate Properties of H-Wave® 
Device, a Small Fiber Stimulator Provides the Basis for a Paradigm Shift of 
Electro -Therapeutic Treatment of Pain with Increased Functional Restoration 
Associated with Human Neuropathies: a Hypothesis. Medical Hypotheses. 
64(5): 1066-7.（SCI） 
二、 可供推廣之研發成果資料 
附件八可供推廣之研發成果資料列出本計畫可能可以申請專利
之項目，更進一步的研究，增加樣本數，確立上述基因實驗結果，應
可申請專利。 
 13
2.6 您是否有領取社會救濟金 □1.否 □2.是 
三、過動 
3.1 您是否無法持續坐著，手或腳會動來動去坐立不安？ □1.否或不知 □2.偶爾 □3.常常 
3.2 您是否很難待在座位上？ □1.否或不知 □2.偶爾 □3.常常 
3.3 您在睡覺時是否很容易翻來覆去？ □1.否或不知 □2.偶爾 □3.常常 
3.4 您是否常打斷他人說話或突然闖入他人的活動？ □1.否或不知 □2.偶爾 □3.常常 
3.5 您是否常常講太多話？ □1.否或不知 □2.偶爾 □3.常常 
3.6 您是否曾被西醫診斷為過動症病人，而需以藥物控制或治療？ □1.否 □2.是 
四、注意力 
4.1 您是否無法完成已開始做的事？ □1.否或不知 □2.偶爾 □3.常常 
4.2 當有人與您說話時並沒有注意聽？□1.否或不知 □2.偶爾 □3.常常 
4.3 您是否容易抓狂？ □1.否或不知 □2.偶爾 □3.常常 
4.4 您是否很難專心？ □1.否或不知 □2.偶爾 □3.常常 
4.5 您是否很難堅持於一項活動？ □1.否或不知 □2.偶爾 □3.常常 
4.6 您是否很難遵循訓令？ □1.否或不知 □2.偶爾 □3.常常？ 
4.7 您是否常常弄丟家裡或工作上的必需品？ □1.否或不知 □2.偶爾 □3.常常 
五、飲食 
5.1 您是否曾經狂吃過(在短時間內迅速消耗大量食物)？  
□1.否 □2.是  年紀______歲時 
5.1.1 如選「是｣，您是否曾在 3 個月中一個禮拜狂吃兩次？ □1.否 □2.是  年紀______歲時 
5.2. 您是否對下列很渴望 
     a. 糖                      □1.不渴望 □2.中等渴望 □3.非常渴望 
     b. 巧克力                  □1.不渴望 □2.中等渴望 □3.非常渴望 
     c. 甜點或碳水化合物(汽水類) □1.不渴望 □2.中等渴望 □3.非常渴望 
     d. 其他，請說明 _________________□1.不渴望 □2.中等渴望 □3.非常渴望 
5.3 您是否曾認為自己對吃有衝動？ □1.否 □2.是 
5.4 您是否會喝過多的水或其他液體或吃冰？ □1.無 □2.有點 □3.的確如此 
5.5 您是否曾被西醫診斷為肥胖症病人，而需以藥物控制或治療？ □1.否 □2.是 
六、抽煙、吃檳榔 
6.1 您是否曾經抽香菸、雪茄或煙斗超過一個月以上？ □1.否 □2.是 
6.2 如果您現在抽煙，平均一天抽多少？ 
□1.從來沒有(跳答 6.3) □2.每天 1 到 10 支 □3.每天 11 支到一包（20 支） 
□4.每天多於一包 □5.偶而抽幾支 □6.只抽幾次即不抽 
6.2.1 請問您幾歲第一次抽煙？ 
□1.10 歲以下 □2.11~20 歲 □3.21~30 歲 □4.31~40 歲 □5.41 歲及以上 
6.2.2 請問您持續抽幾年了？            年（若中途有中斷幾年，請扣除這幾年） 
6.3 您是否有（或曾經有）嚼食檳榔的習慣？  
□1.從來沒有(跳答 7.1) □2.每天 1 到 10 顆 □3.每天 11 到 20 顆  
 15
□1.無 □2.1~2 人 □3.3~5 人 □4.6 人及以上 
9.4.1 與您同時發生最嚴重的職業災害是否有人死亡? □1.否 □2.是 
9.4.2 與您同時發生最嚴重的職業災害的死亡人數?  
□1.1 人 □2.2~3 人 □3.4~5 人 □4.6 人及以上 
9.4.3 與您同時發生最嚴重的職業災害的輕傷人數?  
□1.1 人 □2.2~3 人 □3.4~5 人 □4.6 人及以上 
9.4.4 與您同時發生最嚴重的職業災害的重傷人數?  
□1.1 人 □2.2~3 人 □3.4~5 人 □4.6 人及以上 
9.5 您在發生職業災害後是否有發生肢體殘障? □1.否 □2.是 
9.6 您的殘障等級：□1.輕度 □2.中度 □3.重度 □4.極重度 
9.7 發生最嚴重的職業災害所造成公司財產損失的程度為？ □1.輕微 □2.中度 □3.嚴重 □4.破產 
9.8 您是否曾因為工作不小心或器械操作不當而造成職業傷害？  
□1.不曾 □2.曾經有過，幾次? □1.0 次 □2.1 到 2 次 □3.3 到 5 次 □4.6 次及以上 
9.8.1 那最嚴重的結果是？  □1.擦藥幾天即好 □2.縫合幾針即好 □3.住院幾天即好  
□4.截肢 □5.半身癱瘓 □6.全身癱瘓 
 
訪視結束的時間：      時      分 
訪視者簽名：_______________ 
受訪者簽名：_______________ 
 17
10. 加入 500 μl 含 ethanol 的 buffer B5，並離心 1 分鐘（6000 xg）。移除過濾液，
並再操作一次。在移除 B5 的 washing steps 2 次後，再將 NucleoSpin tube 置於離
心管，並離心 1 分鐘，為了完全移除 B5。 
11.將 NucleoSpin tube 置於另一個乾淨的 1.5 ml 離心管，再以 200 μl 的 10Mm 
Tris/Hcl，ph=9（加熱至 70 ℃）萃取 DNA，離心 1 分鐘（6000 xg）。 所得的過
濾液即可去測 OD 定量 DNA。 
 
 
頭髮― Chelex 100  extract DNA 
Prepare: 
1. autoclaved deionized water 
2. 5% Chelex 100  
表 1. 5% Chelex 100 
20%/5% Chelex Solution  
The DNA Extraction Reagent available from Bio-Rad. The 20% Chelex 
Solution will be prepared and can be diluted to 5% with autoclaved deionized water 
Note: When pipetting Chelex stock solutions, the resin beads must be 
distributed evenly in solutions; this can be achieved by gentle mixing with a stir 
bar in beaker. Also, the pipette tip used for transfer must have a large bore. 
One ml pipette tips are adequate. 
3.10mg/mL Proteinase K 
表 2. 10mg/mL Proteinase K 
若取別種濃度的 Proteinase K 則需配置 10mg/mL 的濃度才可用 
 
 19
 
To extract DNA : 
表 4. To extract DNA(Oral Swbs) 
Step Action 
1. Suspend the swab sample in 1mL of autoclaved deionized water in an autoclaved 
1.5-mL microcentrifuge tube.  
2. Incubate at room temperate for 30 minutes.  
3. Twirl the swab and toothpick for 2 minutes to release the cells from the swab. 
4. Remove the substrate and toothpick. Spin in a microcentrifuge for 2 minutes at 
10000-15000xg（maximum speed ）at room temperature. 
5. Without disturbing the pellet, remove and discard all but 25 μl (or twice the 
volume of the pellet, whichever is greater ) of the supernatant. 
6. Resuspend the pellet in the remaining 25μl by stirring with an autoclaved 
pipette tip. 
7. Add 200µl of 5% chelex in a 1.5-ml microcentrifuge tube. 
8. Add 2µl of 10mg/ml proteinase K.  Mix . 
9. Incubate the sample at 56℃ for15-30 minutes. 
10. Vortex 5-10 seconds. 
11.   Spin down 10-20 seconds. 
12. Boiling water bath for 8 minutes. 
13. Vortex 5-10 seconds 
14. Spin the sample in a microcentrifuge for 2-3 minutes at 10,000-15,000xg 
(maximum speed) at room temperature. The sample is now ready for DNA 
quantitation and the PCR amplification process. 
15. Store the remainder of the sample at either 2-6℃ or –15 to –25℃. 
16. To reuse, thaw sample at room temperature and repeat steps 7-8. 
 
 
 21
附件三   子計畫六：選定之 19 種基因 
（一） 5 HT 2A (5-hydroxytryptamine 2A) receptor gene 
Genotyping of the T/C polymorphism at position 102 of HTR2A was done by 
polymerase chain reaction (PCR) (Bondy et al., 2000) using the primers of 
5’-TCTgCTACAAgTTCTggCTTT-3’, and 5’-CTgCAgCTTTTTCTCTAggg-3’. PCR was 
performed in a final volume of 25 l consisting of 50 ng DNA, 0.6 M of each primer,  
200 M dNTPs, 10 mM Tris -HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, and 1.25U Taq 
polymerase. Annealing was carried out at 60℃ for 30 sec, extension at 72℃ for 30 sec, 
and denaturation at 95℃ for 30 sec for 35 cycles. PCR products were digested with 10 U 
Msp I (Roche) for 14 hr and separated on a 2% agarose gel (FMC NuSieve 3:1). The 
102T-allele (T102) showed a PCR product fragment of 342 bp and the 102C-allele (C102) 
showed two PCR product fragments of 126 bp and 216 bp after digestion with restriction 
enzyme of MspI. The laboratory personnel was blind to the origin and diagnoses of the 
DNA probes.  
 
（ 二 ） 5-HTTLPR (serotonin transporter promoter region 
polymorphism) gene 
An insertion/deletion polymorphism has been reported in the promoter region 
(5HTTLPR) (Heils et al., 1996). The polymorphism consists of two allelic forms and is 
associated with different 5-HTT promoter activity. The allele designated “l” has greater 
transcriptional activity and subsequently more serotonin reuptake than the short allele “s”, 
which is associated with a more restricted transcriptional activity of the promoter leading 
to lower functional expression of the 5 HTT (Heils et al., 1996). 
The 5-HTTLPR-promoter region polymorphism was characterized as described by 
Ebstein et al. (1997) and Manor et al. (2001). Polymerase chain reaction (PCR) 
amplification was performed by using Taq Polymerase and a high denaturing temperature 
(98 ℃ ). The primers used to generate a 484/528-bp fragment were SIL-1 
5’-ggCgTTgCCgCTCTgAATgC-3’ and SIL-2 5’-gAgggACTgAgCTggACAACCAC-3’. 
The reaction mixture contains the following components: 1 x reaction buffer, 0.5 M 
primers, 100 ng DNA, 200 M dATP, dTTP, dCTP, 100 M dGTP, and 100 M   
7-deaza-2’-dGTP, 1 U Taq Polymerase, and 12 % DMSO in a total volume 15 L. After 
 23
personality traits, especially reward-dependence trait. 
The allelic variants of the 1a adrenoceptor was analyzed by using Polymerase 
chain reaction as described by Tsai et al. (2001). The PCR reaction mixture contained 0.2 
mM dNTP, 1.0 mM MgCl2, 1 M primers of 5’ -ATgCTCCAgCCAAgAgTTCA-3’ and 
5’-TCCAAgAAgAgCTggCCTTC-3’. After initial denaturation at 94℃ for 5 min, 35 
cycles of PCR reaction were performed under conditions of 95℃ for 30 sec, 57℃ for 45 
sec, and 72℃ for 1 min. The PCR products were digested with 5 units of Pst I at 37℃ 
for 4 hr and analyzed by using a 2% ethidium bromide-stained agarose gel. The digested 
products of 502 bp were type “C”, and that of 457 bp and 45 bp were type “T”. 
 
（五）ADRA2R ( 2a adrenergic receptor gene)  
The genotyping of the biallelic polymorphism in the promoter region of the 2a 
adrenergic receptor gene (ADRA2R) was conducted according to a protocol described by 
Lario et al. (1997). A 522-bp fragment from the promoter region of the ADRA2R gene 
was amplified by PCR using a sense primer (5’-TCACACCggAggTTACTTCCCTCg-3’) 
at position –1417 upstream from the putative origin of the transcription site and an 
antisense primer (5’-TCCgACgACAgCgCgAgTT-3’) at position –913. The PCR reaction 
mixture contained 0.2 mM dNTP, 1.0 mM MgCl2, 1 M of each primer. After initial 
denaturation at 94℃ for 1 min, 35 cycles of PCR reaction were performed under 
conditions of 94℃ for 30 sec, 60℃ for 45 sec, and 72℃ for 1 min. The PCR products 
were digested with 2 units of MspI at 37℃ for 2 hr and analyzed by using a 10% 
nondenaturing polyacrylamide gel and then stained by using ethidium bromide. The 
samples with digested products of 174, 165, 116, 62, and 5 bp were typed as “M”. The 
transversion C->G produces the loss of the 174bp fragment appearing two polymorphic 
bands of 121 and 53 bp that determine the allele “m” ( 121,53,165,116,62, and 5 bp ). 
 
（六）COMT (catechol-O-methyltransferase) 
COMT is a ubiquitous enzyme that catalyzes the O-methylation of several 
catecholamine neurotransmitters, including dopamine, epinephrine, and norepinephrine. 
The enzyme exists in two forms (thermolabile, thermostable) that functionally differ by a 
3-4 –fold variation in enzyme activity. The gene for COMT contains a known Nla III 
 25
Initial denaturation was performed at 94℃ for 3 min, followed by 30 cycles of 
denaturation at 94℃ for 30 sec, annealing at 60℃ for 30 sec, extension at 72℃ for 1 
min, and a single final extension at 72℃ for 1 min. 
CYP2A6*A genotype were determined by digestion of the PCR II product with the 
restriction enzyme Xcm I. CYP2A*A2 contains an Xcm I site, while CYP2A6*A1 does 
not. CYP2A6*B genotypes were determined by digestion of the PCR II product with the 
restriction enzymes BspE I and Bsr I. CYP2A6*B2 contains a BspE I site, while 
CYP2A6*B1 does not. Confirmation of CYP2A6*B2 identification was obtained by 
digestion of all samples with Bsr I, which cleaves CYP2A6*B1, but not CYP2A6*B2. 
Digested products were electrophoresed on 2 % agarose gel stained with ethidium 
bromide and imaged under UV transillumination for scoring.  
 
Table.5 Primers used for PCR amplification of CYP2A6 
Primer name                              sequence 
2A6-Ex3In    5’-AAC CTG ATC GAC TAG GCG TGG TA-3’ 
2A6-Ex4R    5’-GGA GGT TGA CGT GAA CTG GAA GA-3’ 
E3F     5’-GCG TGG TAT TCA GCA ACG GG-3’ 
E3R     5’-TCG TCC TGG GTG TTT TCC TTC-3’ 
 
 
（八）DAT 1 gene 
The alleles at the 3’UTR were determined by PCR using the oligomers and PCR 
conditions reported by Vandenbergh et al., (1992). Following PCR amplification the 
products were electrophoresed in an 8% acrylamide gel with a set of size markers.  
 
（九）DRD2 gene 
 27
reactions were digested in a total volume of 30 l with 6 -8U of Taq A restriction enzyme 
at the manufacturer’s recommended conditions. The result product were separated by 
electrophoresis in 3% agarose gel, and visualized with ethidium bromide staining under 
ultraviolet light. Two alleles were obtained: B1 allele (the uncleaved 459-bp fragment) 
and the B2 allele (the cleaved 267-bp and 192-bp fragments). 
 
C. Data analysis  
Information coded from interview proformas was entered into a computer data base. 
Chi-square test (Yates corrected) and Fisher’s exact test, where appropriate, were 
employed to compare frequency differences of the DRD2 A1 allele between the various 
groups studied.  
Statistical analysis of the fitness of the Hardy-Weinberg equilibrium, and the allelic 
association of TaqI A polymorphism and behavior disorders, were evaluated by 
chi-square test. 
 
D. Terminology 
The term “prevalence of the DRD2 A1 allele” refers to the percent of individuals 
carrying the DRD2 A1/A1 or DRD2 A1/A2 genotype. The term “frequency of the DRD2 
A1 allele” refers to the gene frequency where the total number of DRD2 A1 alleles are 
counted and divided by the total number of haploid sets of chromosomes.  
 
（十）DRD3 gene  
Genotype determination： 
Blood samples were collected with EDTA anticoagulant, and genomic DNA was 
prepared using Resin extraction method (Promega, ). 
Restriction fragment length polymorphism (RFLP) analysis of Msc I  
polymorphism of the DRD3 gene was carried out by using a PCR-based restriction 
analysis according to the method described by Legro et al. (1995). Primers were designed 
 29
L reaction containing 20 M forward (5’  -GCGACTACGTGGTCTACTCG-3’) and 
reverse (5’-AGGACCCTCATGGCCTTG-3’) primers, 2mM each of dATP, dCTP and 
dTTP, one mM each of dGTP and 7 deaza-dGTP, 10% DMSO, and 1x PCR buffer 
(Perkin-Elmer). One unit of Taq polymerase in 1 x PCR buffer was added during a ‘hot 
start’ phase at 82 oC and the DNA was amplified for 40 rounds consisting of denaturation 
at 95℃ for 15 sec, annealing at 58℃ for 15 sec, and extension at 72℃ for 20 sec. A 
first denaturing step at 99℃ for 2 min and last extension step at 72℃ for 10 min were 
also added. Depending on the quality of the amplification, approximately 10 ml PCR 
product was loaded on a 6% nondenaturing polyacrylamide gel, and sizes were estimated 
by comparison with DNA marker. All allele sizes were determined independently by two 
investigators.  
Because of the GC rich nature of the polymorphic region, unless 
5-azaguanadinecompletely replaced guanadine, some heterozygotes were missed, 
producing pseudohomozygosity. This required the identification of the alleles by silver 
staining (Budowle et al., 1991).  
Gels were silver stained using 100 ml of the following reagents: a fixing solution of 
10% ethanol and 0.5% acetic acid for 3 min (twice); 0.1% solution of silver nitrated for 
15 min; distilled water for 30 sec (twice); 1.5% sodium hydroxide and 0.1% 
formaldehyde developing solution for 20 min; distilled water for 30 sec (twice); 0.75% 
aqueous solution of sodium bicarbonate to fix the gel. Adding 5 ml of 2.3M citric acid 
followed by agitation for 10 min stopped color development. The gel was then washed 
several times, placed in distilled water and photographed. A 1-kb DNA ladder was used to 
identify the various repeat alleles by size: 323-bp, 2 repeats; 371-bp, 3 repeats; 419-bp, 4 
repeats; 467-bp, 5 repeats; 515-bp, 6 repeats; 563-bp, 7 repeats; 611-bp, 8 repeats. 
 
（十二）DRD5 
A dinucleotide repeat polymorphism at the DRD5 gene, D5(CT/GT/GA)n were 
studied as described by Sherrington et al. (1993). For amplification of the microsatellite, 
the primers were  designed as DRD5-1 (5’-CgTgTATgATCCCTgCAg-3’) and DRD5-2 
(5’-gCTCATgAgAAgAATggAgTg-3’). For the amplification, primer DRD5-2 was 
labeled with 32P using T4 polynucleotide kinase. Each reaction contained 1 pM of each 
primer and used an annealing temperature of 58℃. The PCR products were then 
separated by a 4% sequencing gel and DRD5(CT/GT/GA)n  repeat alleles were revealed 
by autoradiography. Twelve repeat alleles were found, here designated as : allele 1 (156 
 31
CA repeat alleles of the GABRB3 were determined by a slight modification of the 
procedure of Mutirangura et al. (1992). PCR was performed in a Perkin Elmer GeneAmp 
2400 thermocycler in a total volume of 10- l containing 0.025 g genomic DN  A, 0.2 
M of each primer (GABRB3 -1 5’-CTCTTgTTCCTgTTgCTTTCAATACAC-3’ and 
33P-labled GABRB3-2 5’-CACTgTgCTAgTAgATTCAgCTC-3’), 1.5 mM MgCl2, 200 
M each of dNTP, 0.5 unit Taq Polymerase (BRL) and 1x PCR buffer. The initial 
denaturation was at 94℃ for 4 min followed by 26 cycles at 94℃/1 min, 55℃/1 min, 72
℃/2 min and a final extension of 10 min at 72℃. The PCR products were then separated 
by a 4% sequencing gel and CA repeat alleles were revealed by autoradiography. Twelve 
GA repeat alleles were found, here designated as : G1 (181 bp), G2 (183 bp), G3 (185 bp), 
G4 (187 bp), G5(189 bp), G6 (191 bp), G7 (193 bp), G8 (195 bp), G9 (197 bp), G10(199 
bp), G11 (201 bp), G12 (203 bp). 
 
（十五）G-protein 3 gene (G 3)    
Abnormal signal transduction pathways have been implicated in the pathogenesis of 
bipolar disorder and major depression-proteins are key elements of these pathways in the 
regulation of cellular responses by transmission of signals form receptors to effector 
proteins. In recent years several studies have reported altered levels and activities of 
G-protein  subunits in depressive patients. It has also been demonstrated that G -protein 
3 subunit seems to be a susceptibility factor for major depression and maybe for 
bipolar disorder.  
Genotyping of the C825T polymorphism of G 3 was performed according to the 
polymerase chain reaction (PCR)-based method described by Zill et al. [2000]. A 
standard PCR was carried out in a 25μl volume containing 100ng genomic DNA, 200μ
M of each dNTP, 1.25units Taq DNA Polymerase, and 0.6μΜ of the G 3 -1 primer 
(5’-TGACCCACTTGCCACCCGTGC-3’) and of the G 3  –2 primer  
(5’-GCAGCAGCCAGGGCTGGC-3’). After an initial denaturation step at 95℃ for 5 
min, there were 35 cycles of denaturation at 95℃ for 1 min, annealing at 60℃ for 45s 
and extension at 72℃ for 1 min. An additional final step was performed at 72℃ for 7 
min. The PCR products were digested with 2.5units of BseDI  for 4h, separated by 
electrophoresis in 2.5﹪ agarose gels and visualized by ethidium bromide staining under 
u.v. light. The unrestricted PCR product (TT genotype) has a size of 268 bp. Complete 
restriction (CC genotype) generates bands of 116 and 152bp. 
 
 33
（十八）-opioid-receptor gene (OPRM1) A118G  
Genotyping was performed as described by Bergen et al. (1997).  
（十九）PNMT (phenylethanolamine N-methyltransferase) gene  
PMNT is a candidate gene for a range of psychiatric disorders. Human PNMT is the 
rate-limiting enzyme in the synthesis of epinephrine from norepinephrine (Axelrod and 
Weinshilboum, 1972). Since defects in epinephrine metabolism have been implicated in 
the etiology of attention deficit hyperactivity disorder (ADHD), aggression and anxiety 
(Girardi et al., 1995; Hanna et al., 1996; Klinteberg and Magnusson , 1989; Pliszka et al., 
1994), PMNT is a candidate gene for a range of psychiatric disorders. G-148A and 
G353-A in the promoter region of the PNMT gene. (Wu and Comings, 1999) 
For detection of the G-148A polymorphism of the PNMT gene, standard PCR was 
carried out in a 15 l volume containing 50 ng genomic DNA, 200nM of each primer, 
200 M dNTPs, and 0.6 U Taq DNA Polymerase. The amplification was performed for 
35 cycles with denaturation at 95℃ for 40 sec, annealing temperature 60℃ for G-148A 
for 40 sec and elongation at 72℃ for 40 sec. The amplified products were digested with 
Msp I and the resulting polymorphic fragments were separated on 10 % polyacrylamide 
gel in 1x TBE buffer. Then they were stained with ethidium bromine. The Msp I enzyme 
identifies allele A: 65bp and allele G: 49bp + 16 bp. There are two constant bands at 19 
bp and 17 bp. 
For detection of the G-353A polymorphism of the PNMT gene, standard PCR was 
carried out in a 15 l volume containing 50 ng genomic DNA, 200nM of each primer, 200 
M dNTPs, and 0.6 U Taq DNA Polymerase. The amplification was performed for 35 
cycles with denaturation at 95℃ for 40 sec, annealing temperature 58℃ for G-353A for 
40 sec and elongation at 72℃ for 40 sec. The amplified products were digested with Mnl 
I and the resulting polymorphic fragments were separated on 10 % polyacrylamide gel in 
1x TBE buffer. Then they were stained with ethidium bromine. The Mnl I enzyme 
identifies allele A: 44bp and allele G: 27bp + 17bp. There are two constant bands at 24 bp 
and 18 bp. 
Table.6 PCR primers for the G-148A and G-353A polymorphism of the PNMT gene 
Variant name             primers sequence           PCR product (bp)  
 35
附件四   子計畫六：130 個實驗分析結果 
    
Figure 1 The Polymerase chain reaction (PCR) amplification of region downstream from 
the polyadenylation signal, restriction digest with Taq I and electrophoresis on a 3% 
agarose gel. The far lane on the left has a X174 DNA/Hae III marker. Lane 1 is 
homozygous for A1/A1, lane 2 is heterozygous A1/A2, lane 3 is homozygous for A2/A2. 
 
 
1,353
1,078
872
603
310
281/271
234
194
118(72)
M 1     2     3    4      5     6  
bp
Gene:Gβ3
1
C
Frequency 57.69% 42.31%
39 19
14.62%
Table.7 Prevalence of T/T, T/C, and C/C genotypes
(n=130)
Genotypes T/T T/C C/C
Number
                                Table.8  Frequency ofthe T and C allele. (n=260)
Allele T
72
Prevalence 30.00% 55.38%
 37
 
1,353
1,078
872
603
310
281/271
234
194
118(72)
1     2     3     4     M 
bp
Gene:ADA
118
Figure.3 : The ADA locus encompasses 12 exons spanning approximately 32 Kb and is
located on chromesome 20q 13.11 . The Polymerase chain reaction (PCR) amplification
polymorphism signal, the presence of the ADA2 mutation determines the loss of  restric
M/N N/N
90.77%
                     Table.11  Prevalence ofM/M, M/N, and N/N genotypes (n=130)
Number 0 12
Prevalence 0.00% 9.23%
Genotypes M/M
Table.12 Frequency ofthe M and N allele.
(n=260)
Allele M
Frequency 4.62% 95.38%
N
 39
 
1,353
1,078
872
603
310
281/271
234
194
118(72)
M 1   2   3 
bp
Gene:DRD2β
45
35.71%
                   Table.15  Prevalence of B1/B1, B1/B2, and B2/B2 genotypes (n=126)
Number 21 60
Prevalence 16.67% 47.62%
Figure.5 : The Polymerase chain reaction (PCR) amplification of region downstream from
the polyadenylation signal, restriction digest with Taq I and electrophoresis on a 3% agarose
gel. The far lane on the left has a fX174 DNA/Hae III marker. Lane 1 is h
Genotypes B1/B1 B1/B2 B2/B2
Table.16 Frequency ofthe B1 and B2 allele.
(n=252)
Allele B1
Frequency 40.48% 59.52%
B2
 41
 
726
713 
553 500
427/417/413
311
249
200
151
140
118
100
82
M       1    2       3       4Gene:COMT
C
Frequency 70.54% 15.50%
Table.20  Frequency ofthe H and L allele.
(n=258)
Allele H L
17.05% 6.98%
Number 80 22 9
Prevalence 62.02%
                     Table.19  Prevalence of H/H, H/L, and L/L genotypes (n=129)
Genotypes H/H H/L L/L
Figure.7 : The Polymerase chain reaction (PCR) amplification of exon 4 of the COMT
gene, which falls within the region of chromosome 22q11, restriction digest with NlaⅢ
electrophoresis on 3.5% agarose gel. The far lane on the left has a fX174 DNA/HinfⅠma
 43
 
 
Gene:DRD3 M   1    2     3     4     5    6
726
713553 500
427/417/413
311
249
200
151140 118
100
82
66
48/42/40
24
                    Table.23  Prevalence of A/A, G/G and A/G genotypes (n=129)
A
72
Figure.9 : The Polymerase chain reaction (PCR) amplification of region downstream from
the polyadenylation signal, restriction digest with Msc and electrophoresis on 8%
polyacrylamide gel. The far lane on the left has a f174 Hinf1 marker. Lane 1 and 2 ar
Genotypes A/GG/GA/A
Number 489
Frequency 25.58%74.42%
37.21%6.98%Prevalence 55.81%
Table.24 Frequency of the A and G allele.
(n=258)
Allele G
 45
Blum K, Wood RC, Sheridan PJ, Chen T. Comings DE. Dopamine D2 receptor gene 
variants: association and linkage studies in impulsive, addictive and compulsive disorders. 
Pharmacogenetics 1995; 5:121-141. 
Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C, Jonge S, Rupprecht R, 
Meyer H, Engel RR, Eisenmenger W, and Ackenheil M. Lack of association of serotonin-2A 
receptor gene polymorphism (T102C) with suicidal ideation and suicide. 2000. Am J Med Gen 
(Neuropsychiatric genetics) 96:831-835. 
Castiglione CM, Deinard AS, Speed WC, Sirugo G, Rosenbaum HC, Zhang Y, Grandy DK, 
Grigorenko EL. Bonne-Tamir B, Pakstis AJ, et al. 1995. Evolution of haplotypes at the DRD2 
locus. Am J Hum Genet 57:1445-1456. 
Chong SA, Tan EC, Tan CH, Mahendren R, Tay AHN, and Chua HC. Tardive dyskinesia is 
not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese.2000. Am J Med 
Gen (Neuropsych Genet) 96:712-715. 
Cloninger CR, Adolfsson R, Svrakic NM. 1996. Mapping genes for human personality. Nat 
Genet 12:3-4.  
Cloninger CR, Svrakic DM, Przybeck TR. 1993. A psychobiological model of temperament 
and character. Arch Gen Psychiatry 50:975-990. 
Comings DE, Comings BG, Muhleman D, Dietz G, Shahbahrami B, Tast D Knell E, Kocsis 
P, Baumgarten R, Kovacs BW, Levy DL, Smith M, Kane JM, Leiberman JA, Klein DN, 
MacMurray J, Tosk J, Sverd J, Gysin R, Flanagan S. The dopamine D2 receptor locus as a 
modifying gene in neuropsychiatric disorders. J Am Med Assn 1991; 266:1793-1800. 
Comings DE, Flanagan SD, Dietz G, Muhleman D, Knell E, Gysin R. 1993. The dopamine 
D2 receptor as a major gene in obesity and weight. Biochem Med Metabol Biol 50:176-185. 
Comings DE, Gonzalea N, Wu S, Gade R, Muhleman D, Saucier G, Johnson P, Verde R, 
Rosenthal RJ, Lesieur HR, Rugle LJ, Miller WB, and MacMurray JP. Studies of the 48 bp repeat 
polymorphism of the DRD4 gene in impulsive, compulsive, addictive begaviors: Tourette 
syndrome, ADHD, Pathological gambling, and substance abuse. Am J Med Gen (Neuropsych 
Genet) 1999; 88:358-368. 
Comings DE, Muhleman D and Gysin R. Dopamine D2 receptor (DRD2) gene and 
susceptibility to posttraumatic stress disorder: a study and replication. Biol Psychiatry 1996; 
40:368-372. 
 47
Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, 
Pelkonen O, Huang JD, Evans W, Idle JR, Gonzalez FJ. 1995. A genetic polymorphism in 
coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant 
CYP2A6 alleles. Am J Hum Genet 57:651-660. 
Franke P, Wang T, Nothen MM, Knapp M, Neidt H, Albrecht S, Jahnes E, Propping P, and 
Wolfgang M. 2001. Nonreplication of association between - opioid-receptor gene (OPRM1) 
A118G polymorphism and substance dependence. Am J Med Gen (Neuropsych Genet) 
105:114-119. 
Girardi NL, Shaywitz SE, Shaywitz BA, et al. 1995. Blunted catecholamine responses after 
glucose ingestion in children with attention deficit disorder. Pediatr. Res. 38:539-542. 
Grandy DK, Zhang Y, Civelli O. 1993. PCR detection of the TaqI A RFLP at the DRD2 
locus. Hum Mol Genet 2:2197. 
Greger V,Knoll JHM,Woolf E,Glatt K,Tyndale RF,DeLorey TM ,Olsen RW,Tobin 
AJ,Sikela JM, Nakatsu Y,Brilliant MH, Whiting PJ,Lalande M 1996.The aminobutyric acid 
receptor 3 subunit gene(GABRG3) is tightly linked to the  subunit gene(GABAG5) on  
human chromosome 15q11-q13 and is transcribed in the same orientation.Genomics 26,258-264. 
Grice DE, Leckman Jf, Pauls DL, Kurlan R, Kidd KK, Pajstis AJ, Chang FM, Buxbaum JD, 
Cohen DJ, Gelernter J. Linkage disequilibrium of an allele at the dopamine D4 receptor locus 
with Tourette’s syndrome by TDT. Am J Hum Genet 1996; 59:644-652. 
Hanna GL, Ornitz EM, Hariharan M. 1996. Urinary epinephrine excretion during 
intelligence testing in attention-deficit hyperactivity disorder and normal boys. Biol. Psychiatry 
40:553-555. 
Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch P. 1996. Allelic variation 
of human serotonin transporter gene expression. J Neurochem 66:2621-2624. 
Hamon M. The main features of central 5-HT1A receptors. In: Serotoninergic neurons and 
5-HT receptors in the CNS, Baumgarter HG, Gothert M (editors). Heidelberg: Springer. pp. 
239-268. 
Hodge Cw,Chappelle AM,Samaon HH 1995.GABAergic transmission in the nucleus 
accumbens is involved in the termination of ethanol self-administration in 
rats.Alcoholism,Clinical and Experimental Research 19,1486-1493. 
Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H, and Ebstein, RP. 
 49
Liljequist S,Engel T 1982.Effects of GABAergic agonists and antagonists on various 
ethanol-induced behavioral changes.Psychopharmacology 78,71-77. 
Manor I, Eisenberg J, Tyano S, Sever Y, Cohen H, Ebstein RP, and Kotler M. Family-based 
association study of the serotonin trnasporter promoter region polymorphism (5-HTTLPR) in 
attention deficit hyperactivity disorder. 2001. Am J Med Gen (Neuropsychiatric genetics) 
105:91-95. 
Minassian BA,DeLoery T,Olsen R, Bryanat A, Homanics G, Firestone L,Skinner S,Handforth A, 
Nasataourian A, Delgado-Escueta A 1996.GABRB3:a gene involved in epilepsy of 
Angelman Syndrome(AS).Ameriacan Journal of Human Genetics 59,A273. 
Muglia P, Jain U, Macciardi F, and Kennedy JL. Adult attention deficit hyperactivity 
disorder and the dopamine D4 receptor gene.2000. Am J Med Gen (Neuropsychiatric genetics) 
96:273-277. 
Nakatsu Y, Tyndale RF, DeLorey TM, Durham-Pierce D, Gardaner JM, McDanel HJ, Nguyen Q, 
Wagstaff J, Lalande M,Sikela JM, Olsen RW, tobin AJ,Brilliant MH,1993.A cluster of three 
GABA receptor subunit genes is deleted in a neurological mutant of the mouse p 
locus.Nature 364,448-450. 
Noble EP, Noble RE, Ritchie T, Syndulko K, Bohlman MC, Noble LA, Zhang Y, Sparkes 
RS, Grandy DK. 1994a. D2 dopamine receptor gene and obesity. Int J Eat Disorders 15:205-217. 
Noble EP, Zhang X, Ritchie TL, and Sparkes RS. Haplotypes at the DRD2 locus and severe 
alcoholism. Am. J. Med. Gen (Neuropsych Genet) 2000; 96:622-631. 
Oscarson M, Gullsten H, Rautio A, Bernal ML, Sinues B, Dahl ML, Stengard JH, Pelkonen 
O, Raunio H, Ingelman-Sundberg M. 1998. Genotyping of human cytochrome P450 2A6 
(CYP2A6), a nicotine C-oxidase. FEBS Lett 438:201-205. 
Persico AM, Militerni R, Bravaccio C, Schneider C, Melmed R, Trillo S, Montecchi F, 
Palermo MT, Pascucci T, Puglisi-Allegra S, Reichelt KL, Conciatori M, Baldi A, and Keller F. 
Adenosin deaminase alleles and autistic disorder: case-control and family-based association 
studies. 2000. Am J Med Gen (Neuropsychiatric genetics) 96:784-790. 
Preuss UW, Koller G, Bahlmann M, Soyka M, Bondy B. No association between suicidal 
begavior and 5-HT2A- T102C polymorphism in alcohol dependents. 2000. Am J Med Gen 
(Neuropsychiatric genetics) 96:877-878. 
Rassnick S, D’Amico E, Riley E, Koob GF 1993.GABA antagonistand benzodiazepine partial 
 51
methods, population genetics, and relevance to studies of tobacco dependence. 2000. Am J Med 
Gen (Neuropsychiatric genetics) 96:638-645. 
 53
DRD4 DRD4-1 5’-GCGACTACGTGGTCTACTCG-3’ Lichter et 
al., 1993 
PCR and 
agarose gel 
or maybe 
DRD4-2 5’-AGGACCCTCATGGCCTTG-3’ 
DRD5 DRD5-1 5’-CgTgTATgATCCCTgCAg-3’  Sherrington 
et al., 1993 
PCR and 
32P-labeled 
primer  
DRD5-2 5’-gCTCATgAgAAgAATggAgTg-3’ 
PNMT PNMT-148-1 5’-CgggACAAgTACggAgCC-3’  Wu and 
Comings,19
99 
PCR and 
MspI PNMT-148-2 5’-CCATCTCCCTTAgTgTCC-3’ 
PNMT-353-1 5’-gTCTCCACCTCgAATCAg-3’ PCR and 
Mnl I PNMT-353-2 5’-CCATCTCTCTTCTCCAgC-3’ 
DRD3 DRD3-1 5’-GGGCTATGGCATCTCTGAGT-3’  Legro et al., 
1995 
PCR and 
MscI DRD3-2 5’-AAGTAGTTGGTGGTAGTCTG-3’ 
GABRB3 GABRB3-1 5’-CTCTTgTTCCTgTTgCTTTCAATACAC-3’  Mutirangura 
et al., 1992 
32P-labled 
primer, PCR GABRB3-2 5’-CACTgTgCTAgTAgATTCAgCTC-3’ 
HTR1A HTR1A-1 5’-CTgAgggAgTAAggCTggAC-3’   Wu and C 
omings, 
(1999) 
PCR and 
DdeI HTR1A-2 5’-gAAgAAgACCgAgTgTgTCCTA-3’ 
GABRA3 GABRA3-1 5’-gggTTCAggAgACTgCACAgCAA-3’  Gade-Anda
volu et al., 
(1998) 
PCR and 32P or 
fluorescence-l
abeled primer 
GABRA3-2 5’-TCCTgAgggCAgggTCTCTgA-3’ 
ADRA2R ADRA2R-1 5’-TCACACCggAggTTACTTCCCTCg-3’ Lario et al. 
(1997) 
PCR and 
MspI ADRA2R-2 5’-TCCgACgACAgCgCgAgTT-3’ 
ADRA1R 
‘ 
ADRA1R-1 5’-ATgCTCCAgCCAAgAgTTCA-3’ Tsai et al., 
(2001) 
PCR and 
PstI ADRA1R-2 5’-TCCAAgAAgAgCTggCCTTC-3’ 
 
 55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.11  : The ADA locus encompasses 12 exons spanning approximately 32 Kb and 
is located on  chromesome 20q 13.11 . The Polymerase chain reaction (PCR) 
amplification  polymorphism signal, the presence of the ADA2 mutation determines the 
loss of  restriction digest with Taq 1 and electrophoresis on 3% agarose gel. The far lane 
on the right has a fX174 DNA/HaeⅢ marker. Lane 1, 2 are PCR products, lane 3  is 
heterozygous for  M/N, and lane 4 is homozygous for N/N. In our experiments, we 
didn't find homozygous genotype for M/M. 
 
Table.27 Prevalence of M/M, M/N, and N/N genotypes (n=8) 
Genotypes M/M M/N N/N 
Number 0 0 8 
Prevalence 0.00% 0.00% 100.00% 
 
Table.28 Frequency ofthe M and N allele. (n=16) 
Allele M N 
Frequency 0.00% 100.00% 
1,353
1,078
872
603
310
281/271
234
194
118(72)
1     2     3     4     M 
bp
Gene:ADA
 57
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.13  : The Polymerase chain reaction (PCR) amplification of region downstream 
from the polyadenylation signal, restriction digest with Taq I and electrophoresis on a 3% 
agarose gel. The far lane on the left has a fX174 DNA/Hae III marker. Lane 1 is 
homozygous for B1/B1, lane 2 is heterozygous B1/B2, lane 3 is homozygous for B2/B2. 
 
Table.31 Prevalence of B1/B1, B1/B2, and B2/B2 genotypes (n=8) 
Genotypes B1/B1 B1/B2 B2/B2 
Number 0 7 1 
Prevalence 0.00% 87.50% 12.50% 
 
Table.32 Frequency ofthe B1 and B2 allele. (n=16) 
Allele B1 B2 
Frequency 43.75% 56.25% 
 
 
 
1,353
1,078
872
603
310
281/271
234
194
118(72)
M 1   2   3 
bp
Gene:DRD2β
 59
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.15  : The Polymerase chain reaction (PCR) amplification of exon 4 of the COMT 
gene, which falls within the region of chromosome 22q11, restriction digest with NlaⅢ 
electrophoresis on 3.5% agarose gel. The far lane on the left has a fX174 DNA/HinfⅠ
marker. Lane 1 is the product of the Polymerase chain reaction (PCR). Lane 2 are 
homozygous for H/H, lane 3 are heterozygous for  H/L, and lane 4 are homozygous for 
L/L . 
 
Table.35 Prevalence of H/H, H/L, and L/L genotypes (n=8) 
Genotypes H/H H/L L/L 
Number 6 1 1 
Prevalence 75.00% 12.50% 12.50% 
 
Table.36 Frequency ofthe H and L allele. (n=16) 
Allele H L 
Frequency 81.25% 18.75% 
 
 
726
713 
553 500
427/417/413
311
249
200
151
140
118
100
82
M       1    2       3       4Gene:COMT
C
